QbD is often promoted to improve quality, enhance efficiencies, and reduce the cost of manufacturing pharmaceutical products such as tablets and products. This article provides a critical assessment of this view. It is argued that the promotion appears to be an attempt to market the expertise in statistical analyses. This distorted view in fact, appears to be causing confusion and hindrance in accepting the QbD approach. A discussion is provided highlighting the underlying issues in this regard. Link for the article Please click here for the complete article